Total Payments
$252,951
2024 Payments
$56,550
Companies
14
Transactions
200
Medicare Patients
516
Medicare Billing
$121,156
Payment Breakdown by Category
Consulting$138,595 (54.8%)
Other$84,591 (33.4%)
Travel$16,824 (6.7%)
Research$7,950 (3.1%)
Food & Beverage$4,991 (2.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $138,595 | 37 | 54.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $63,578 | 17 | 25.1% |
| Honoraria | $19,490 | 8 | 7.7% |
| Travel and Lodging | $16,824 | 49 | 6.7% |
| Unspecified | $7,950 | 10 | 3.1% |
| Food and Beverage | $4,991 | 78 | 2.0% |
| Grant | $1,523 | 1 | 0.6% |
Payments by Type
General
$245,002
190 transactions
Research
$7,950
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Blue Earth Diagnostics Limited | $76,835 | 13 | $0 (2023) |
| Novocure Inc. | $45,064 | 64 | $0 (2024) |
| Seagen Inc. | $39,178 | 29 | $0 (2023) |
| PFIZER INC. | $33,873 | 29 | $0 (2024) |
| SERVIER PHARMACEUTICALS LLC | $15,134 | 11 | $0 (2024) |
| AbbVie, Inc. | $14,440 | 27 | $0 (2019) |
| F. Hoffmann-La Roche AG | $10,133 | 8 | $0 (2023) |
| Telix Pharmaceuticals | $9,329 | 7 | $0 (2024) |
| Janssen Global Services, LLC | $3,410 | 2 | $0 (2021) |
| Servier BioInnovation | $2,941 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $56,550 | 48 | PFIZER INC. ($33,873) |
| 2023 | $97,610 | 60 | Seagen Inc. ($39,178) |
| 2022 | $62,152 | 34 | Blue Earth Diagnostics Limited ($38,765) |
| 2021 | $10,207 | 6 | F. Hoffmann-La Roche AG ($3,686) |
| 2020 | $5,736 | 7 | Novocure Inc. ($2,032) |
| 2019 | $4,026 | 11 | AbbVie, Inc. ($2,147) |
| 2018 | $5,958 | 16 | AbbVie, Inc. ($4,275) |
| 2017 | $10,714 | 18 | AbbVie, Inc. ($8,019) |
All Payment Transactions
200 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $6.30 | General |
| Category: Oncology | ||||||
| 11/04/2024 | SERVIER PHARMACEUTICALS LLC | — | Consulting Fee | Cash or cash equivalent | $2,075.00 | General |
| 11/04/2024 | SERVIER PHARMACEUTICALS LLC | — | Food and Beverage | In-kind items and services | $67.50 | General |
| 10/14/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $1,018.33 | Research |
| Study: Phase 1 Astrocytoma study which is a study looking at the combination of Vorasidenib and Pembrolizumab | ||||||
| 09/25/2024 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $8.33 | General |
| Category: Oncology | ||||||
| 07/19/2024 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $27.03 | General |
| Category: Oncology | ||||||
| 07/03/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 06/27/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $355.83 | Research |
| Study: Phase 1 Astrocytoma study which is a study looking at the combination of Vorasidenib and Pembrolizumab | ||||||
| 06/25/2024 | PFIZER INC. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,460.00 | General |
| Category: Oncology | ||||||
| 06/25/2024 | PFIZER INC. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $474.08 | General |
| Category: Oncology | ||||||
| 06/25/2024 | PFIZER INC. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $76.77 | General |
| Category: Oncology | ||||||
| 06/17/2024 | PFIZER INC. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,150.00 | General |
| Category: Oncology | ||||||
| 06/17/2024 | PFIZER INC. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $583.63 | General |
| Category: Oncology | ||||||
| 06/17/2024 | PFIZER INC. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $382.20 | General |
| Category: Oncology | ||||||
| 06/17/2024 | PFIZER INC. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $250.78 | General |
| Category: Oncology | ||||||
| 06/17/2024 | PFIZER INC. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $77.40 | General |
| Category: Oncology | ||||||
| 06/17/2024 | PFIZER INC. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $47.07 | General |
| Category: Oncology | ||||||
| 06/17/2024 | PFIZER INC. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $29.97 | General |
| Category: Oncology | ||||||
| 05/31/2024 | SERVIER PHARMACEUTICALS LLC | — | Travel and Lodging | Cash or cash equivalent | $138.36 | General |
| 05/31/2024 | SERVIER PHARMACEUTICALS LLC | — | Food and Beverage | Cash or cash equivalent | $55.91 | General |
| 05/09/2024 | SERVIER PHARMACEUTICALS LLC | — | Travel and Lodging | Cash or cash equivalent | $335.30 | General |
| 05/09/2024 | SERVIER PHARMACEUTICALS LLC | — | Travel and Lodging | Cash or cash equivalent | $269.90 | General |
| 05/06/2024 | SERVIER PHARMACEUTICALS LLC | — | Consulting Fee | Cash or cash equivalent | $5,395.00 | General |
| 05/03/2024 | PFIZER INC. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,690.00 | General |
| Category: Oncology | ||||||
| 05/03/2024 | PFIZER INC. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $474.08 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN OPEN-LABEL, MULTICENTER, PHASE II STUDY OF HIGH-DOSE HERCEPTIN WITH PERJETA IN PATIENTS WITH CENTRAL NERVOUS SYSTEM METASTASES FROM HER2 POSITIVE METASTATIC BREAST AN OPEN-LABEL, MULTICENTER, PHASE II STUDY OF HIGH-DOSE HERCEPTIN WITH PERJETA IN PATIENTS WITH CENTRAL NERVOUS SYSTEM METASTASES FROM HER2 POSITIVE METASTATIC BREAST CANCER | F. Hoffmann-La Roche AG | $4,171 | 2 |
| Phase 1 Astrocytoma study which is a study looking at the combination of Vorasidenib and Pembrolizumab | Servier BioInnovation | $2,941 | 6 |
| PATRICIA | F. Hoffmann-La Roche AG | $817.78 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 119 | 215 | $91,178 | $27,509 |
| 2022 | 3 | 108 | 211 | $85,997 | $28,698 |
| 2021 | 4 | 157 | 268 | $106,212 | $37,023 |
| 2020 | 4 | 132 | 247 | $101,336 | $27,926 |
Total Patients
516
Total Services
941
Medicare Billing
$121,156
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 72 | 157 | $68,138 | $20,469 | 30.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $11,080 | $2,892 | 26.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 20 | 22 | $5,500 | $2,103 | 38.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 11 | 20 | $6,460 | $2,046 | 31.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 66 | 158 | $68,406 | $22,387 | 32.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 31 | 42 | $10,500 | $4,397 | 41.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $7,091 | $1,913 | 27.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 97 | 198 | $80,620 | $27,709 | 34.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 29 | 35 | $8,750 | $3,924 | 44.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 20 | 20 | $12,126 | $3,800 | 31.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 11 | 15 | $4,716 | $1,590 | 33.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 72 | 166 | $72,044 | $19,053 | 26.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 23 | 39 | $9,750 | $3,651 | 37.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 18 | 18 | $11,790 | $3,109 | 26.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 19 | 24 | $7,752 | $2,114 | 27.3% |
About Dr. Priya Kumthekar, MD
Dr. Priya Kumthekar, MD is a Neurology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/25/2009. The National Provider Identifier (NPI) number assigned to this provider is 1649410036.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Priya Kumthekar, MD has received a total of $252,951 in payments from pharmaceutical and medical device companies, with $56,550 received in 2024. These payments were reported across 200 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($138,595).
As a Medicare-enrolled provider, Kumthekar has provided services to 516 Medicare beneficiaries, totaling 941 services with total Medicare billing of $121,156. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Hematology & Oncology
- Location Chicago, IL
- Active Since 02/25/2009
- Last Updated 11/08/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1649410036
Products in Payments
- Axumin (Drug) $76,835
- TUKYSA (Drug) $73,051
- Optune (Device) $35,114
- ILLUCCIX (Drug) $9,329
- Perjeta (Biological) $6,740
- Oncology (Device) $3,843
- Herceptin (Biological) $2,633
- Neuroblate (Device) $124.95
- Tibsovo (Drug) $6.30
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Chicago
Mr. Augusto Miravalle, Md, MD
Neurology — Payments: $1.1M
Neurology $1.1M
Adil Javed
Neurology — Payments: $1.0M
Neurology $1.0M
Douglas Nordli, Md, MD
Neurology — Payments: $654,190
Neurology $654,190
Dr. Dusan Stefoski, Md, MD
Neurology — Payments: $610,165
Neurology $610,165
Dr. Danny Bega, M.d, M.D
Neurology — Payments: $432,383
Neurology $432,383
Tatyana Simuni, Md, MD
Neurology — Payments: $385,696
Neurology $385,696